Journal of Clinical Oncology · 2008 · 11 citations · 0 references
MedicineOncologyPharmacologyCancer PharmacologyGastrointestinal OncologyMetastasisAngiogenesis In CancerEsophageal CancerGastric CancerGastrointestinal Cancer PharmacotherapyMalignant NeoplasmsMetastatic Gastrointestinal CancerEsophageal Cancer PharmacotherapyGastric Cancer PharmacotherapyMetastatic Gastric CancerOxaliplatin-based TherapyVascular Endothelial Growth FactorVascular Endothelial Growth Factor InhibitionVascular Endothelial Growth Factor InhibitorsVegf Pathway Inhibition
15608 Background: VEGF (vascular endothelial growth factor) has a central role in angiogenesis, tumor growth, and metastasis. VEGF expression is increased in gastric cancer. Inhibition of VEGF results in impaired growth and metastasis of gastric cancer in preclinical models. Bevacizumab, an anti-VEGF monoclonal antibody, has demonstrated anti-tumor activity in multiple diseases. This phase II study was undertaken to determine the effects of adding bevacizumab to a regimen of docetaxel and oxaliplatin. Methods: The primary endpoint was time to progression (TTP) in patients with locally advanced or metastatic adenocarcinoma of the stomach or GEJ treated with docetaxel, oxaliplatin and bevacizumab. Previously untreated patients with a performance status (PS) of 0–1 were eligible for this study. Patients received bevacizumab 7.5 mg/kg, docetaxel 70 mg/m2, and oxaliplatin 75 mg/m2 administered on day 1 of a 21 day cycle. Results: A total of 8 patients (median age 44, males 75%, gastric 50%) were enrolled on the study. Median PS was 1. Partial responses were documented in 4 patients and stable disease in 4. No treatment related deaths were observed. The most commonly reported grade 3–4 toxicities were neutropenia (38%), fever (13%), acute neuropathy (13%), and hypertension (13%). One hospitalization was for neutropenic fever. Gastrointestinal (GI) perforation occurred in 2 patients after the second cycle. Perforation was not found at the tumor site in the patient who required surgery. The site of perforation could not be ascertained in the second patient who was managed medically. Both patients had had no prior surgical resection of the primary tumor. For now the study is accruing one patient at a time until a total of 10 to ensure patient safety. Conclusions: The regimen of docetaxel, oxaliplatin and bevacizumab appears to be very active. The development of GI perforations in 2 patients was of concern. At this time, bevacizumab should not be used in gastric or GEJ cancers outside of a clinical trial until its safety is well established. No significant financial relationships to disclose.